GFI1B and acute myeloid leukemia: The lack of a synergistic interaction in the combination in non-AML cells can be explained by the low GFI1B expression in these cell types, which suggests few overlapping nonhematologic toxicities, such as hepatotoxicity,30 and a wide therapeutic window for the combination.